BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35744791)

  • 1. Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.
    Galati S; Sainas S; Giorgis M; Boschi D; Lolli ML; Ortore G; Poli G; Tuccinardi T
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
    Gehlot P; Vyas VK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery a series of novel inhibitors of human dihydroorotate dehydrogenase: Biological activity evaluation and molecular docking.
    Ren X; Liu X; Hua M; Dai Y; Ren X; Sui C; Li X; Jiang Z; Tian M; Yang B
    Chem Biol Drug Des; 2024 Jan; 103(1):e14388. PubMed ID: 37926553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
    Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y
    Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiratricol, a thyroid hormone metabolite, has potent inhibitory activity against human dihydroorotate dehydrogenase.
    Cao S; Ma H; Xu Z; Fang W; Huang J; Huang Y
    Chem Biol Drug Des; 2023 Jul; 102(1):1-13. PubMed ID: 37088711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a human dihydroorotate dehydrogenase (hDHODH) pharma-similarity index approach with scaffold-hopping strategy for the design of novel potential inhibitors.
    Shih KC; Lee CC; Tsai CN; Lin YS; Tang CY
    PLoS One; 2014; 9(2):e87960. PubMed ID: 24504131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Optimization of Novel
    Zhou X; Gou K; Xu J; Jian L; Luo Y; Li C; Guan X; Qiu J; Zou J; Zhang Y; Zhong X; Zeng T; Zhou Y; Xiao Y; Yang X; Chen W; Gao P; Liu C; Zhou Y; Tao L; Liu X; Cen X; Chen Q; Sun Q; Luo Y; Zhao Y
    J Med Chem; 2023 Nov; 66(21):14755-14786. PubMed ID: 37870434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
    Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F
    Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potential natural dihydroorotate dehydrogenase inhibitors and their synergism with brequinar via integrated molecular docking, dynamic simulations and in vitro approach.
    Khairy A; Hammoda HM; Celik I; Zaatout HH; Ibrahim RS
    Sci Rep; 2022 Nov; 12(1):19037. PubMed ID: 36351991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel series of hDHODH inhibitors with anti-pulmonary fibrotic activities.
    Lu K; Zhao Y; Wu G; Hu H; Wang M; Gong G; Jiang Y
    Bioorg Chem; 2019 May; 86():44-51. PubMed ID: 30685643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent.
    Alberti M; Poli G; Broggini L; Sainas S; Rizzi M; Boschi D; Ferraris DM; Martino E; Ricagno S; Tuccinardi T; Lolli ML; Miggiano R
    Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):386-396. PubMed ID: 38805244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.
    Li C; Zhou Y; Xu J; Zhou X; Huang Z; Zeng T; Yang X; Tao L; Gou K; Zhong X; Chen Q; Luo Y; Zhao Y
    Eur J Med Chem; 2022 Aug; 238():114489. PubMed ID: 35640328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Optimization and Structure-Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase.
    Zeng F; Quan L; Yang G; Qi T; Zhang L; Li S; Li H; Zhu L; Xu X
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31370178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.
    Sainas S; Pippione AC; Lupino E; Giorgis M; Circosta P; Gaidano V; Goyal P; Bonanni D; Rolando B; Cignetti A; Ducime A; Andersson M; Järvå M; Friemann R; Piccinini M; Ramondetti C; Buccinnà B; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2018 Jul; 61(14):6034-6055. PubMed ID: 29939742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.
    Li C; Zhou Y; Xu J; Zhou X; Liu S; Huang Z; Qiu Z; Zeng T; Gou K; Tao L; Zhong X; Yang X; Zhou Y; Su N; Chen Q; Zhao Y; Luo Y
    Eur J Med Chem; 2022 Dec; 243():114737. PubMed ID: 36115209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
    Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
    J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of docking-based 3D QSAR models for the design of substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors.
    Vyas VK; Ghate M
    SAR QSAR Environ Res; 2013 Aug; 24(8):625-45. PubMed ID: 23714018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design.
    Vyas VK; Qureshi G; Oza D; Patel H; Parmar K; Patel P; Ghate MD
    Bioorg Med Chem Lett; 2019 Apr; 29(7):917-922. PubMed ID: 30738663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
    Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
    SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 3,4-Dihydro-2
    Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.